Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021; 23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Rayner Kay Jin Tan, Jane Mingjie Lim, MSW, and Jeremiah Kah Wai Chan, MSc
Merits and drawbacks of U = U messaging are ethically and clinically complex, and drawbacks could harm patients in whom viral suppression is hard to achieve.
AMA J Ethics. 2021; 23(5):E418-422. doi:
10.1001/amajethics.2021.418.
E. Berryhill McCarty, MA, MSHCPM and Lance Wahlert, PhD
Global transformation demanded by COVID-19 prompts consideration of how prior epidemics have shaped our cultural and sociological understandings of health care experiences.
AMA J Ethics. 2021; 23(5):E423-427. doi:
10.1001/amajethics.2021.423.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.